(PharmaNewsWire.Com, February 07, 2018 ) Extracorporeal membrane oxygenation, or ECMO, is a treatment used for patients with life-threatening heart and/or lung problems. It provides long-term breathing and heart support and is used only when all of the standard treatments for those problems have already been tried. ECMO can support patients for days to weeks while doctors treat their underlying illness. ECMO is performed using a heart-lung bypass machine similar to the one used during open heart surgery. The ECMO machine, often referred to as a “circuit,” is quite large and contains sterile plastic tubing that moves blood from your baby to the “ECMO lung” and then back to your child. The ECMO lung adds oxygen to the blood and removes carbon dioxide, as a healthy lung would.
The growth of the market can be credited to the rise in the number of cases of cardiovascular and respiratory diseases, the increase in the adoption of ECMO as a bridge to lung transplantation, increasing number of ECMO centers, conferences and training programs to increase awareness, and technological advancements. In addition, the increase in the geriatric population and the number of people suffering from diseases in populous countries are factors that are projected to drive the growth of the market. Moreover, surge in the adoption of unhealthy lifestyle and the subsequent development of lifestyle ailments are projected to further expand the COPD incidence rate. Identified risk factors, such as the increase in the tobacco consumption trend in both, males and females, are further supporting the growth of the market. Be that as it may, complications associated with extracorporeal membranes oxygenation machines such as bleeding, infections, and technical failures along with high cost and lack of skilled professionals is a challenge to the market.
The Europe Extracorporeal Membrane Oxygenation Machine Market segmentation by Modality and Application. On the basis of Modality, it is segmented into Veno-Arterial (VA), Veno-Venous (VV) and Arterio-Venous (AV). The veno-venous (VV) segment is expected to account for the largest share of this market segment. The arteriovenous (AV) segment is projected to grow at the highest CAGR in the coming years. On the basis of application, it is segmented into Respiratory, Cardiac and Extracorporeal Cardiopulmonary Resuscitation (ECPR). The respiratory segment accounts for the largest share of this market segment.
On the basis of geography, the market is analyzed under various regions namely Germany, France, U.K., Italy and Spain. Europe accounts for the second largest share of the market. The favorable reimbursement scenario, rising incidence of lung cancer, and the presence of a large number of ECMO centers are expected to boost the market.
Europe Extracorporeal Membrane Oxygenation Machine Market Leaders are Getinge Group, Medtronic plc, LivaNova PLC, XENIOS AG, Terumo Corporation, MicroPort Scientific Corporation, NIPRO Corporation, OriGen Biomedical Inc., ALung Technologies Inc. and EUROSETS S.r.l.
About Market Data Forecast: The publisher of this report is Market Data Forecast whose forte lies in Market research and Business Intelligence. Handling both individual and corporate clients across multiple business domains they offer syndicated/customized research to suit the client’s research objective. Their research reports section offers a wide variety of market studies ranging from all-encompassing comprehensive market studies to product specific niche markets covering North America among other regions of the global market as well. For more info kindly visit, www.marketdataforecast.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
